Abstract nr
Central Nervous System
Proffered Paper Session: Central Nervous System
Chair: M. Preusser (Austria)
Chair: R. Soffietti (Italy)
09:00
2900
Predictors of survival in glioblastoma patients treated with fotemustine at first relapse after Stupp regimen: Analysis of GLIOSTRY (GLIOblastoma regiSTRY) of the AINO (Italian Association of Neuro-Oncology)
Speaker: G. Lombardi (Italy)
09:15
2901
Phase 2 study of VB-111, an anti-cancer gene therapy, as monotherapy followed by combination of VB-111 with bevacizumab, in patients with recurrent glioblastoma
Speaker: A. Brenner (USA)
09:30
2902
GEINO-11: A prospective multicenter, open label, phase II pilot clinical trial to evaluate safety and efficacy of Dacomitinib, a pan-HER irreversible inhibitor, in patients with recurrent glioblastoma with EGFR amplification or presence of EGFRvIII mutation
Speaker: J.M. Sepúlveda (Spain)
09:45
2903
Identifying the correct patient (pt) population for ABT-414: Biomarker assays for epidermal growth factor receptor (EGFR) in pts with glioblastoma (GBM)
Speaker: M.J. van den Bent (Netherlands)
10:00
Discussant : W. Wick (Germany)
10:10
2904
Patterns of response and relapse of primary central nervous system lymphomas (PCNSL) following first line of high-dose methotrexate-based chemotherapy (hdMTX): Independent review of a prospective ANOCEF randomized phase II trial
Speaker: E. Tabouret (France)
10:25
2905
Genomic characterization of brain metastases and paired primary tumors reveals branched evolution and potential therapeutic targets
Speaker: P. Brastianos (USA)
10:40
Discussant : M. Brada (United Kingdom)
10:50
26LBA
LATE BREAKING ABSTRACT: Does valproic acid improve survival in glioblastoma? A meta-analysis of randomized trials in newly diagnosed glioblastoma
Speaker: M. Weller (Switzerland)
11:00
Discussant : R. Soffietti (Italy)